TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR SKIN REPLACEMENTS AND SUBSTITUTES

Skin replacements and substitute products currently represent one of the most promising applications of tissue engineering. In 2009, the potential United States (U.S.) market for tissue-engineered skin replacements and substitutes totaled approximately $18.9 billion, based on a target patient population of approximately 5.0 million. By the year 2019, the total potential target population for the use of tissue-engineered skin replacements and substitutes is expected to increase to 6.4 million, resulting in a potential U.S. market of approximately $24.3 billion in the year 2019. The largest potential area of this market is represented by products for the treatment of diabetic, pressure, and venous ulcers; followed by products for abdominal wall repair, then products for other applications (e.g., dermabrasion site treatment products, fasciotomy site treatment products, Mohs surgery site treatment products, skin graft donor site treatment products, and traumatic wound repair products); and products for burn treatment; face, head, and neck reconstruction; and breast augmentation/repair.

This newest report from Medtech Insight provides the U.S. market forecast for tissue-engineered skin replacement and substitute products for the years 2009 to 2014, an estimation of the potential market for the years 2009 and 2019, and a competitive analysis (including market shares for the leading suppliers to this market). In addition, this new report also provides an overview of tissue-engineered skin replacement and substitutes currently being marketed in the U.S., an update on emerging products as well as a clinical overview of the primary clinical applications for tissue-engineered skin replacements and substitutes (including up-to-date incidence and prevalence numbers for associated diseases).

This is the final report in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. Previous reports in this series have provided analyses of the U.S. markets for cardiac and vascular, musculoskeletal, neurosurgical, urologic, and organ regeneration tissue engineering and cell transplantation products.